GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (FRA:QIA) » Definitions » Capital Expenditure

Qiagen NV (FRA:QIA) Capital Expenditure : €-157.78 Mil (TTM As of Jun. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Qiagen NV Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Qiagen NV's cash flow for capital expenditures for the three months ended in Jun. 2024 was €-36 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2024 was €-157.78 Mil.

Qiagen NV Capital Expenditure Historical Data

The historical data trend for Qiagen NV's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Capital Expenditure Chart

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -247.40 -250.08 -182.78 -140.97 -149.29

Qiagen NV Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.73 -38.46 -47.89 -35.29 -36.15

Qiagen NV Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-157.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (FRA:QIA) » Definitions » Capital Expenditure
Comparable Companies
CRL MEDP EXAS RDNT SHC RVTY NTRA NEOG VCYT GH TMO DHR XSWX:LONN IQV A IDXX MTD ILMN SHSE:603259 WAT
Traded in Other Exchanges
QGEN:USA 1QGEN:Italy QIAd:UK 0RLT:UK QIA:Germany QIA:Germany QGE2:Austria
Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Website
https://www.qiagen.com
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Executives
Dr. Metin Colpan Supervisory Board

Qiagen NV Headlines

No Headlines